ivci:bordeaux_2025

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revision Previous revision
Next revision		 Previous revision
ivci:bordeaux_2025 [2025/05/29 20:39] – [Next Steps and Closing Discussion] nbunkerivci:bordeaux_2025 [2025/05/30 08:47] (current) – fkaag
Line 5: Line 5:
 === Shaping the Future of Global Vaccine Interoperability === === Shaping the Future of Global Vaccine Interoperability ===
  
-The International Summit on Vaccine Coding & Standards was held May 9, 2025 in Bordeaux. There vaccine code experts, immunization registry leaders, and public health professionals gathered to tackle one of the most critical challenges in immunization today—ensuring that vaccine data is accurate, interoperable, and useful across borders.+The first in-person meeting of the International Vaccine Code (IVC) Initiative was held in Bordeaux, bringing together experts from across Europe and Americas to explore the technical, clinical, and operational challenges of vaccine coding. With over 35 participants attending both in person and online, the event marked a major milestone in building a collaborative global community focused on improving how vaccinations are digitally recorded and shared. 
 + 
 +The meeting opened with a review of IVC's goals and accomplishments so far, including monthly calls, the launch of the IVC website, interviews with countries and organizations, and work on mapping and metrics. Participants shared their backgrounds and expectations through an interactive poll, revealing a wide range of experience levels and strong interest in improving global harmonization, tracking vaccine histories, and understanding the role of NUVA—a terminology developed by SYADEM—as a pivot code system for vaccines. 
 + 
 +The core of the meeting focused on in-depth presentations about NUVA and its integration into systems like SNOMED CT, WHO Drug, national registries, and EU projects such as ePIL and the European Vaccination Card (EVC). Real-world use cases from Luxembourg, Canada, the U.S., and Qatar demonstrated the challenges of managing and reconciling vaccine data across fragmented systems. NUVA’s conceptual framework of valences emerged as a unifying method for linking diverse codes and improving clinical decision support. 
 + 
 +Toward the end of the meeting, discussions shifted to sustainability and future governance. Participants debated the pros and cons of forming a formal organization versus aligning with existing structures like SNOMED or HL7. While no final decision was made, there was strong consensus that IVC fills a unique gap and that its work should be nurtured through partnerships and “matchmaking” with larger efforts already underway. 
 + 
 +The energy and feedback from participants confirmed that this work is both needed and technically on the right track. Moving forward, the IVC Initiative will focus on expanding its community, deepening partnerships, and continuing to serve as a bridge between technical solutions and public health realities in the field of immunization.
  
-This one-day summit was a unique opportunity to collaborate, share insights, and help shape the future of vaccine coding and interoperability. 
  
  
 ====== Bordeaux 2025 Meeting Summary ====== ====== Bordeaux 2025 Meeting Summary ======
  
-**Date:** May 9, 2025   +**Date:** May 9, 2025  \\ 
-**Location:** Radisson Blu Hotel, Bordeaux, France   +**Location:** Radisson Blu Hotel, Bordeaux, France  \\ 
-**Event:** International Summit on Vaccine Coding & Standards  +**Event:** International Summit on Vaccine Coding & Standards  \\
 **Hosted by:** International Vaccine Codes Initiative (IVCI) **Hosted by:** International Vaccine Codes Initiative (IVCI)
  
Line 36: Line 43:
 ===== Session Summaries ===== ===== Session Summaries =====
  
-=== Foundations & Global Perspectives ===+  FOUNDATIONS AND GLOBAL PERSPECTIVES
  
 ==== NUVA: What It Is and Why It Matters ==== ==== NUVA: What It Is and Why It Matters ====
Line 45: Line 52:
  
  
-=== Key Takeaways ===+=== Key Points ===
  
 **Origins and Evolution**   **Origins and Evolution**  
Line 87: Line 94:
  
 A demonstration of the NUVA mapping platform was shared:   A demonstration of the NUVA mapping platform was shared:  
-[https://nuva.syadem.com/mapping](https://nuva.syadem.com/mapping)+[[https://nuva.syadem.com/mapping]]
  
 === Additional Notes === === Additional Notes ===
Line 93: Line 100:
  
 ==== How NUVA Uses Valences to Standardize Vaccine Codes ==== ==== How NUVA Uses Valences to Standardize Vaccine Codes ====
-//Speaker: Jean-Louis Koeck//+//Speaker: Jean-Louis Koeck (Syadem)//
  
 This presentation provided critical clinical context for understanding the valence model at the heart of NUVA. This presentation provided critical clinical context for understanding the valence model at the heart of NUVA.
  
-== Key Takeaways ==+=== Key Points ===
  
   * **Core Definitions**: Jean-Louis began by clearly defining "Vaccine" and "Antigen"—foundational concepts in immunology shared globally. While basic, these helped establish common ground for a diverse audience.   * **Core Definitions**: Jean-Louis began by clearly defining "Vaccine" and "Antigen"—foundational concepts in immunology shared globally. While basic, these helped establish common ground for a diverse audience.
Line 110: Line 117:
     - Vaccine prescription using valence labels rather than commercial product names     - Vaccine prescription using valence labels rather than commercial product names
  
-== In Summary ==+=== In Summary ===
 Valences offer a **common clinical language** to assess protection, regardless of which product or national code system is used. This session made clear that valences are the **core bridge** between vaccination data and actionable immunization guidance. Valences offer a **common clinical language** to assess protection, regardless of which product or national code system is used. This session made clear that valences are the **core bridge** between vaccination data and actionable immunization guidance.
  
  
 ==== The NUVA Extension to SNOMED CT ==== ==== The NUVA Extension to SNOMED CT ====
-*Speakers: Suzy Roy & Peter Williams (SNOMED International)*  +//Speakers: Suzy Roy & Peter Williams (SNOMED International)//
  
 This presentation explained how NUVA is being integrated into the SNOMED CT ecosystem to support broader adoption and interoperability. This presentation explained how NUVA is being integrated into the SNOMED CT ecosystem to support broader adoption and interoperability.
Line 147: Line 154:
  
  
-=== Real-World Use Cases – Global & European Union ===+  REAL-WORD USE CASES - GLOBAL AND EUROPEAN UNION
  
 ==== EU Strategy for Cross-Border Vaccination Records ==== ==== EU Strategy for Cross-Border Vaccination Records ====
-*Speaker: Georgios Margetidis*   +//Speaker: Georgios Margetidis, Health and Digital European Agency (HaDEA)// 
-*Notes to be added*+ 
 +=== Key points === 
 +Georgios presented the frame for the European Commission (EC) actions in the field of digital health. 
 + 
 +According to the European treaties, health is a national competence of Member States. Apart from specific cases regarding cross-border continuity of care, the EC actions can only be incentives. This has been achieved so far through studies, recommendations, joint actions and voluntary groups. 
 + 
 +The European Health Data Space (EHDS) regulation, published in March 2025, creates a new context for digital health, with the obligation for Member States to progressively build up interoperability across electronic health records both for primary and secondary use of data. 
 + 
 +An harmonized approach for recording administered vaccines would be a significant contribution to this objective. Patient summaries, including vaccination history, should be exchangeable across all Member States by March 2029. 
 +=== In summary === 
 +The EHDS regulation allows the EC to become prescriptive on interoperability.
  
 ==== View from the Industry (ePIL & NUVA Integration) ==== ==== View from the Industry (ePIL & NUVA Integration) ====
Line 209: Line 226:
  
  
-=== Real-World Use Cases – Countries ===+  REAL-WORK USE CASES - COUNTRIES
  
 ==== Luxembourg Experience ==== ==== Luxembourg Experience ====
-//Speaker: Maud Delporte* (Agence eSanté Luxembourg)//+//Speaker: Maud Delporte (Agence eSanté Luxembourg)//
  
 Maud Delporte shared the ongoing efforts in Luxembourg to digitize and centralize vaccine histories through the **Carnet de Vaccination Électronique (CVE)**—a national immunization registry built with NUVA at its core. Maud Delporte shared the ongoing efforts in Luxembourg to digitize and centralize vaccine histories through the **Carnet de Vaccination Électronique (CVE)**—a national immunization registry built with NUVA at its core.
Line 368: Line 385:
  
  
- +  IMPLEMENTING NUVA FOR INTEROPERABILITY
-=== Implementing NUVA for Interoperability ===+
  
 ==== Mapping Across Code Systems ==== ==== Mapping Across Code Systems ====
Line 412: Line 428:
  
 ==== Metrics on Code Systems ==== ==== Metrics on Code Systems ====
-*Speaker: François Kaag (IVCI/SYADEM)*+//Speaker: François Kaag (IVCI/SYADEM)//
  
 François Kaag introduced a method for using NUVA to generate metrics that evaluate the completeness, precision, and redundancy of other vaccine coding systems. These metrics can help developers understand the strengths and limitations of their systems and support better cross-system alignment. François Kaag introduced a method for using NUVA to generate metrics that evaluate the completeness, precision, and redundancy of other vaccine coding systems. These metrics can help developers understand the strengths and limitations of their systems and support better cross-system alignment.
  
-==== Key Points ====+=== Key Points ===
  
   * **Abstract vs. Concrete Vaccines**: François clarified the terminology around **abstract vaccines**—concepts that describe the vaccine type or valence structure without referring to a branded product. Examples:   * **Abstract vs. Concrete Vaccines**: François clarified the terminology around **abstract vaccines**—concepts that describe the vaccine type or valence structure without referring to a branded product. Examples:
Line 477: Line 493:
 The consensus: IVC should position itself as a collaborative infrastructure partner—bridging multiple organizations working toward better vaccine interoperability. The consensus: IVC should position itself as a collaborative infrastructure partner—bridging multiple organizations working toward better vaccine interoperability.
  
-===== To Be Added ===== 
  
-Each section above contains placeholders. Please return and fill in: 
-  * Technical and clinical details of each presentation. 
-  * Examples or screenshots shown (if any). 
-  * Audience questions and feedback from each session. 
-  * Any significant quotes or memorable moments from speakers. 
  
  
Line 489: Line 499:
  
  
-==== Slide decks ====+===== Slide decks =====
 ^ Slides  ^ Presenter  ^ Organization  ^ ^ Slides  ^ Presenter  ^ Organization  ^
 | **TRAINING SESSION**  | | | | **TRAINING SESSION**  | | |
  • ivci/bordeaux_2025.1748551179.txt.gz
  • Last modified: 2025/05/29 20:39
  • by nbunker